Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Q3 2025 value amounting to $382.4 million.

  • Crinetics Pharmaceuticals' Change in Acquisitions & Divestments rose 15298.19% to $382.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 12922.4%. This contributed to the annual value of $575.8 million for FY2024, which is 7079.33% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments stood at $382.4 million, which was up 15298.19% from $224.0 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $382.4 million for Q3 2025, and its period low was $244000.0 during Q4 2021.
  • For the 5-year period, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments averaged around $108.0 million, with its median value being $86.7 million (2023).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments tumbled by 9811.66% in 2021, and later skyrocketed by 2887049.18% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $244000.0 in 2021, then soared by 28870.49% to $70.7 million in 2022, then increased by 22.62% to $86.7 million in 2023, then skyrocketed by 112.24% to $184.0 million in 2024, then soared by 107.85% to $382.4 million in 2025.
  • Its Change in Acquisitions & Divestments was $382.4 million in Q3 2025, compared to $224.0 million in Q2 2025 and $306.5 million in Q1 2025.